Biotronik announced the publication of promising clinical results regarding its Pulsar-18 stent platform. Adding to the similarly encouraging data collected in the earlier 4EVER and PEACE trials, the new results — published in Clinical Medical Insights: Cardiology — further confirm the safety and efficacy of the Pulsar-18 self-expanding nitinol stent, with positive patency results for very challenging cases of femoropopliteal disease.

The nation's top consumer, patient and labor advocates recently praised the proposed Stage 3 Meaningful Use rules, describing how they would help ensure health information technology (IT) meets the needs of patients and families.